{
    "ticker": "PXMD",
    "name": "PaxMedica, Inc.",
    "description": "PaxMedica, Inc. is a biopharmaceutical company focused on developing innovative therapies for the treatment of central nervous system (CNS) disorders. Founded in 2018, PaxMedica aims to address the unmet medical needs of patients suffering from conditions such as autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) through its proprietary drug development platform. The company's lead product candidate, PAX-101, is an investigational treatment that leverages a novel mechanism of action aimed at improving the neuropsychiatric symptoms associated with these disorders. PaxMedica is dedicated to conducting rigorous clinical trials to validate the efficacy and safety of its therapies, with a commitment to improving the quality of life for patients and their families. The company's mission is to advance scientific understanding and treatment options for complex CNS conditions, utilizing a patient-centered approach in all its endeavors. As it progresses through clinical development, PaxMedica seeks to collaborate with healthcare providers, researchers, and advocacy groups to foster awareness and support for those affected by these conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2018",
    "website": "https://www.paxmedica.com",
    "ceo": "Howard J. M. K. H. Kahn",
    "social_media": {
        "twitter": "https://twitter.com/PaxMedica",
        "linkedin": "https://www.linkedin.com/company/paxmedica/"
    },
    "investor_relations": "https://www.paxmedica.com/investor-relations",
    "key_executives": [
        {
            "name": "Howard J. M. K. H. Kahn",
            "position": "CEO"
        },
        {
            "name": "Richard W. H. Kahn",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "PAX-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "PaxMedica, Inc. | Innovating CNS Disorder Therapies",
        "meta_description": "Explore PaxMedica, Inc., a biopharmaceutical company dedicated to developing innovative therapies for CNS disorders such as autism and ADHD. Learn about our mission and products.",
        "keywords": [
            "PaxMedica",
            "CNS Disorders",
            "Autism Treatment",
            "ADHD Treatment",
            "Biopharmaceuticals",
            "PAX-101"
        ]
    },
    "faq": [
        {
            "question": "What is PaxMedica focused on?",
            "answer": "PaxMedica is focused on developing therapies for the treatment of central nervous system disorders, including autism and ADHD."
        },
        {
            "question": "Who is the CEO of PaxMedica?",
            "answer": "Howard J. M. K. H. Kahn is the CEO of PaxMedica, Inc."
        },
        {
            "question": "Where is PaxMedica headquartered?",
            "answer": "PaxMedica is headquartered in New York, New York, USA."
        },
        {
            "question": "What is PaxMedica's lead product candidate?",
            "answer": "PaxMedica's lead product candidate is PAX-101, aimed at treating neuropsychiatric symptoms associated with CNS disorders."
        },
        {
            "question": "When was PaxMedica founded?",
            "answer": "PaxMedica was founded in 2018."
        }
    ],
    "competitors": [
        "NTRB",
        "AXSM",
        "PTON",
        "SAGE"
    ],
    "related_stocks": [
        "MRNA",
        "GILD",
        "AMGN",
        "BIIB"
    ]
}